

## THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following best describes TAR-200?**
  - Internal radioactive implant
  - Wafer-based chemotherapy implant
  - Intravesical drug delivery system for gemcitabine
- 2. The Phase III THOR trial evaluating erdafitinib versus chemotherapy for patients with metastatic UBC who experienced disease progression after 1 or 2 prior treatments demonstrated which of the following outcomes?**
  - Significant benefit was observed with erdafitinib in overall response rate (ORR) and progression-free survival (PFS) only
  - Significant benefit was observed with erdafitinib in overall survival only
  - Significant benefit was observed with erdafitinib in ORR, PFS and overall survival
- 3. In the Phase III CheckMate 274 trial, adjuvant nivolumab reduced the risk of disease progression or death in which patients with high-risk muscle-invasive bladder cancer?**
  - High PD-L1 levels
  - Intention-to-treat population
  - Both high PD-L1 levels and intention-to-treat population
  - Neither high PD-L1 levels nor intention-to-treat population
- 4. Which of the following side effects has been associated with enfortumab vedotin?**
  - Rash
  - Diarrhea
  - Peripheral neuropathy
  - Rash and diarrhea only
  - All of the above
- 5. Disitamab vedotin is an antibody-drug conjugate targeting which of the following?**
  - Nectin-4
  - HER2
  - FGFR3
  - TROP2